MentionFox
Home › Stakes › Theravance Biopharma, Inc.
5%+ stakes · Schedule 13D and 13G

Theravance Biopharma, Inc.: 5%+ holders

Who has reported owning 5% or more of Theravance Biopharma, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more2
Filings5
Latest filing2026-09-25

Theravance Biopharma, Inc. has 5 Schedule 13D or 13G filings on record since 2026-02-17. 2 holders' latest filing reports 5% or more of ordinary share $0.00001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Madison Avenue International LP17.7%9,212,252SCHEDULE 13G/A, 2026-08-142026-06-30
Newtyn Management, LLC6.7%3,434,191SCHEDULE 13G/A, 2026-08-142026-06-30
Weiss Asset Management LP0%0SCHEDULE 13D/A, 2026-09-252026-09-23

Timeline

FiledHolderPercentFiling
2026-02-17Newtyn Management, LLC8.5%SCHEDULE 13G/A
2026-03-25Weiss Asset Management LP14.5%SCHEDULE 13D/A
2026-08-14Madison Avenue International LP17.7%SCHEDULE 13G/A
2026-08-14Newtyn Management, LLC6.7%SCHEDULE 13G/A
2026-09-25Weiss Asset Management LP0%SCHEDULE 13D/A

Tools for this story

Each opens in a new tab, filled in for Theravance Biopharma, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/theravance-biopharma
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Theravance Biopharma, Inc. 5%+ holders: 2 at 5% or more, largest Madison Avenue International LP 17.7%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/theravance-biopharma